Company: STAA
Filing Date: 2025-02-21
Form Type: 10-K
Source: 0000950170-25-024813
Chunk: 69

Company: STAAR SURGICAL CO
Filing Date: 2025-02-21
Form: 10-K
Item: Item 1B
Chunk 69
---
$100 was invested at the closing price of our common stock on the last trading day of fiscal year 2019 and all dividends (if any) were reinvested. We have never paid dividends on our common stock and have no present plans to do so.  Stockholder returns over the indicated period should not be considered indicative of future performance.  

Prepared by Zacks Investment Research, Inc. Used with Permission. All rights reserved.

    Total Returns Index for Fiscal Years:
     
    2019

    2020

    2021

    2022

    2023

    2024

    STAAR Surgical Company
     
    $
    100.00

    $
    230.42

    $
    265.56

    $
    141.17

    $
    90.76

    $
    70.39

    The Nasdaq Composite Index

    100.00

    144.12

    176.09

    118.80

    171.83

    227.37

    S&P 400 Health Care Index

    100.00

    131.76

    146.72

    117.30

    117.90

    125.56

ITEM 6.	[Reserved]

33

ITEM 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is intended to promote understanding of our financial condition and results of operations. You should read the following discussion and analysis of our financial condition and results of operations in conjunction with the Consolidated Financial Statements and the Notes to those statements included in this Annual Report. This discussion includes forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including those described in this Annual Report in Item 1A. “Risk Factors.” 

Overview

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. We are the leading manufacturer of phakic implantable lenses used worldwide in corrective or “refractive” surgery.  We have been dedicated solely to ophthalmic surgery for over 40 years. Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom